T. Rowe Price Associates
ORIC icon

T. Rowe Price Associates’s Oric Pharmaceuticals ORIC Stock Holding History

T. Rowe Price Associates’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.7M Buy
6,617,554
+1,229,771
+23% +$11.2M 0.01% 782
2026
Q1 		$68.3M Buy
5,387,783
+2,092,661
+64% +$23.8M 0.01% 701
2025
Q4 		$27M Buy
3,295,122
+423,795
+15% +$4.88M ﹤0.01% 988
2025
Q3 		$34.5M Buy
2,871,327
+108,412
+4% +$1.14M ﹤0.01% 907
2025
Q2 		$28M Buy
2,762,915
+1,430,055
+107% +$9.6M ﹤0.01% 885
2025
Q1 		$7.44M Buy
1,332,860
+37,835
+3% +$331K ﹤0.01% 1166
2024
Q4 		$10.5M Buy
1,295,025
+180,140
+16% +$1.65M ﹤0.01% 1144
2024
Q3 		$11.4M Sell
1,114,885
-74,342
-6% -$735K ﹤0.01% 1120
2024
Q2 		$8.41M Sell
1,189,227
-377,509
-24% -$3.38M ﹤0.01% 1134
2024
Q1 		$21.5M Buy
1,566,736
+915,175
+140% +$10.9M ﹤0.01% 959
2023
Q4 		$6M Buy
651,561
+606,446
+1,344% +$4.39M ﹤0.01% 1171
2023
Q3 		$274K Sell
45,115
-17,949
-28% -$147K ﹤0.01% 2372
2023
Q2 		$490K Buy
63,064
+3,725
+6% +$21.2K ﹤0.01% 2143
2023
Q1 		$339K Hold
59,339
– – ﹤0.01% 2288
2022
Q4 		$350K Hold
59,339
– – ﹤0.01% 2315
2022
Q3 		$191K Buy
59,339
+6,900
+13% +$27.6K ﹤0.01% 2558
2022
Q2 		$235K Sell
52,439
-11,221
-18% -$44.8K ﹤0.01% 2536
2022
Q1 		$340K Buy
63,660
+15,891
+33% +$143K ﹤0.01% 2502
2021
Q4 		$702K Buy
+47,769
New +$745K ﹤0.01% 2217

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIHC Capital Management Central $104M AUM

T. Rowe Price Associates's ORIC Position: Q2 2026 in Review

T. Rowe Price Associates increased its Oric Pharmaceuticals (ORIC) stake by 23% in Q2 2026, buying an estimated $11.2M and bringing the position to 6,617,554 shares worth $71.7M. The position accounts for 0.01% of the portfolio, ranked #782.

T. Rowe Price Associates first reported a position in ORIC in Q4 2021 and has held it in 19 quarters since. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • T. Rowe Price Associates held 6,617,554 shares of Oric Pharmaceuticals worth $71.7M as of Q2 2026.
  • T. Rowe Price Associates bought 1,229,771 Oric Pharmaceuticals shares in Q2 2026, an estimated $11.2M.
  • Oric Pharmaceuticals made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #782 holding.
  • T. Rowe Price Associates first reported a position in Oric Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.